A ‘Holy Grail’ Sleep Apnea Pill Could Be On The Market Next Year

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.
By Published On: Gennaio 12, 2026Categories: DesignCommenti disabilitati su A ‘Holy Grail’ Sleep Apnea Pill Could Be On The Market Next Year

Share This Story, Choose Your Platform!

About the author : admin